Clinical trial
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic…
NCT00431795 · Hellenic Oncology Research Group, Other · Terminated
Key facts
| NCT number | NCT00431795 |
|---|---|
| Title | Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer |
| Official title | A Multicenter Randomized Phase II Study of Second Line Chemotherapy With Epirubicin( Farmorubicin) Versus the Pegylated Liposomal Doxorubicin in Advanced Breast Cancer Patients |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Pegylated liposomal doxorubicin (Caelyx), Epirubicin |
| Enrollment | 100 |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Feb 6, 2007 |
| Last update posted | Feb 13, 2013 |
| Countries | Greece |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: